C07K 2317/00
Immunoglobulins specific features
C07K2317/00 (Immunoglobulins specific features) appears on 30,508 US grants and 59,149 published applications in this corpus.
Search patents in C07K- Granted patents
- 30,508
- Published applications
- 59,149
- Assignees
- 9,722
- Inventors
- 64,683
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 7 | 0 |
| 1988 | 7 | 0 |
| 1989 | 12 | 0 |
| 1990 | 17 | 0 |
| 1991 | 14 | 0 |
| 1992 | 18 | 0 |
| 1993 | 44 | 0 |
| 1994 | 32 | 0 |
| 1995 | 44 | 0 |
| 1996 | 84 | 0 |
| 1997 | 179 | 0 |
| 1998 | 241 | 0 |
| 1999 | 270 | 0 |
| 2000 | 249 | 0 |
| 2001 | 231 | 78 |
| 2002 | 233 | 505 |
| 2003 | 201 | 1283 |
| 2004 | 223 | 805 |
| 2005 | 191 | 972 |
| 2006 | 353 | 1011 |
| 2007 | 419 | 1044 |
| 2008 | 499 | 1060 |
| 2009 | 588 | 1512 |
| 2010 | 732 | 1548 |
| 2011 | 822 | 1764 |
| 2012 | 906 | 1757 |
| 2013 | 1078 | 1879 |
| 2014 | 1221 | 2234 |
| 2015 | 1375 | 2461 |
| 2016 | 1496 | 2879 |
| 2017 | 1672 | 2990 |
| 2018 | 1687 | 2996 |
| 2019 | 1829 | 3381 |
| 2020 | 2048 | 3597 |
| 2021 | 2010 | 3965 |
| 2022 | 2009 | 4078 |
| 2023 | 1777 | 4007 |
| 2024 | 2069 | 4500 |
| 2025 | 2109 | 3863 |
| 2026 | 1503 | 2980 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 2317/70Characterized by effect upon binding to a cell or to an antigenIndexing code18,580
- C07K 2317/20Characterized by taxonomic originIndexing code16,226
- C07K 2317/50Characterized by immunoglobulin fragmentsIndexing code16,011
- C07K 2317/30Characterized by aspects of specificity or valencyIndexing code12,532
- C07K 2317/90Characterized by kinetic aspects or by stability of the immunoglobulinIndexing code11,618
- C07K 2317/60Characterized by non-natural combinations of immunoglobulin fragmentsIndexing code6,862
- C07K 2317/10Characterized by their source of isolation or productionIndexing code2,447
- C07K 2317/40Characterized by post-translational modificationIndexing code1,795
All 9 subgroupsShow fewer
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Methods for treating or preventing asthma by administering an il-4r antagonist8 Oct 2026US 2026/0306627 A1Regeneron Pharmaceuticals, Inc.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Recombinant altered antibodies and methods of making altered antibodies1,968US 5,225,539 AMedical Research Council · 1993